Clinical trials
Renal Insufficiency trials in Sweden
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 3 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Unknown status | 4 |
| Recruiting | 3 |
| Terminated | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sahlgrenska University Hospital | 7 |
| Karolinska Institutet | 4 |
| Uppsala University | 3 |
| AstraZeneca | 2 |
| Vastra Gotaland Region | 2 |
| Alnylam Pharmaceuticals | 1 |
| Ascelia Pharma AB | 1 |
| Biogen | 1 |
| Dr Christopher Marguerie | 1 |
| GE Healthcare | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency | 33 |
| Renal Insufficiency, Chronic | 6 |
| Heart Failure | 4 |
| Diabetes Mellitus | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Cardiovascular Diseases | 2 |
| Coronary Artery Disease | 2 |
| Hemolysis | 2 |
| Kidney Diseases | 2 |
| Kidney Failure, Chronic | 2 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.